Xtandi ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatas audzēji - endokrīnā terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Zejula ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

zejula

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastiski līdzekļi - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Somnols 7,5 mg apvalkotās tabletes লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

somnols 7,5 mg apvalkotās tabletes

grindeks, as, latvia - zopiklons - apvalkotā tablete - 7,5 mg

Imovane 7,5 mg apvalkotās tabletes লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

imovane 7,5 mg apvalkotās tabletes

sanofi winthrop industrie, france - zopiklons - apvalkotā tablete - 7,5 mg

Epromul 220 mg apvalkotās tabletes লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

epromul 220 mg apvalkotās tabletes

pharmaswiss ceska republika s.r.o., czech republic - naproksēna nātrija sāls - apvalkotā tablete - 220 mg

Zolpidem Sandoz 10 mg apvalkotās tabletes লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

zolpidem sandoz 10 mg apvalkotās tabletes

sandoz d.d., slovenia - zolpidēma tartrāts - apvalkotā tablete - 10 mg

Stilnox 10 mg apvalkotās tabletes লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

stilnox 10 mg apvalkotās tabletes

sanofi winthrop industrie, france - zolpidēma tartrāts - apvalkotā tablete - 10 mg

Hypnogen 10 mg apvalkotās tabletes লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

hypnogen 10 mg apvalkotās tabletes

zentiva, k.s., czech republic - zolpidēma tartrāts - apvalkotā tablete - 10 mg

Apealea ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

apealea

inceptua ab - paclitaxel - olnīcu jaunveidojumi - antineoplastic agents, taxanes - apealea kopā ar carboplatin ir norādīts ārstēšanai pieaugušiem pacientiem ar pirmās recidīva platīna‑jutīga epitēlija olnīcu vēzi, galvenais peritoneālās vēzi un olvados vēzis.

Tyruko ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.